Iovance Biotherapeutics, Inc. (NasdaqGM: IOVA)
Health Care · Biotechnology · US
$14.61
-0.10% today · +567.6% 1Y
Iovance Biotherapeutics, Inc. (NasdaqGM: IOVA) operates in the Biotechnology industry within the Health Care sector. The company is valued at $6.62B and employs 975 people.
Over the last twelve months the share price has gained 567.6%, trading between 1.76 and 15.30.
Tweenvest scores Iovance Biotherapeutics, Inc. across four factors: quality 37/100, value 70/100. Its strongest factor is value.
IOVA price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $6.62B
- Revenue (TTM)
- $324.97M
- P/E
- —
- EPS
- -0.71
- Dividend yield
- —
- Beta (5Y)
- 0.76
- 52-week high
- $15.30
- 52-week low
- $1.76
- Avg volume (3M)
- —
- Shares outstanding
- 452.97M
- Employees
- 975
- Next earnings
- —
About Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical development stage, is committed to discovering and bringing to market cancer immunotherapy solutions. Its core mission involves leveraging the patient's own immune system to effectively combat and eradicate cancerous cells. The company is presently conducting six Phase 2 clinical trials. These include study C-144-01, evaluating its primary experimental compound, lifileucel, for individuals with advanced melanoma. Another trial, C-145-04, is assessing lifileucel's potential for treating cervical cancer that is recurrent, metastatic, or persistent. Additionally, investigational product LN-145 is undergoing evaluation in trial C-145-03 for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. maintains strategic alliances and licensing arrangements with several distinguished entities, including H. Lee Moffitt Cancer Center, M.D. Anderson Cancer Center, Ohio State University, the Centre hospitalier de l'Université de Montreal, Cellectis S.A., and Novartis Pharma AG. Established in 2007, the company was previously known as Lion Biotechnologies, Inc. It adopted its current name, Iovance Biotherapeutics, Inc., in June 2017. Its corporate offices are located in San Carlos, California.
- ISIN
- US4622601007
- Founded
- 2007
- Listed since
- Oct 15, 2010
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Praxis Precision Medicines, Inc.NasdaqGS: PRAX | $7.26B | $254.06 | -2.23% |
| Alkermes plcNasdaqGS: ALKS | $6.81B | $40.38 | -0.57% |
| Biocytogen Pharmaceuticals (Beijing) Co., Ltd.SEHK: 2315 | $6.75B | HK$69.20 | +2.59% |
| Gan & Lee Pharmaceuticals.SHSE: 603087 | $6.71B | CN¥75.52 | -2.43% |
| Grifols, S.A.BME: GRF | $6.62B | €10.02 | +1.42% |
| Immunovant, Inc.NasdaqGS: IMVT | $6.29B | $29.81 | -2.17% |
| GRAIL, Inc.NasdaqGS: GRAL | $6.28B | $136.62 | -2.82% |
| Kodiak Sciences Inc.NasdaqGM: KOD | $6.26B | $98.84 | -1.03% |
Figures last refreshed Oct 11, 2026.